AI startup BioinvestGPT correctly predicted the outcome of five of six high-profile drug trials, including the negative result for Novartis' del-desiran, which missed its late-stage goal in September …
Databricks chief information officer Naveen Zutshi was named an Executive of the Year for deploying Genie, an AI agent that lets the company's roughly 11,000 employees query internal data, conduct res…
Cellular Intelligence, the Boston-based startup formerly known as Somite AI, added Moderna co-founder Robert "Bob" Langer and Meta chief AI scientist Yann LeCun to its scientific advisory board, along…
Novo Nordisk is deploying Anthropic's Claude Science model directly into its drug research and development workflows, according to CIO.com, as part of a strategy to become the most AI-driven healthcar…
Anthropic has confirmed it operates a wet biology lab where its AI models are used to run physical experiments, according to Eric Kauderer-Abrams, Anthropic's head of life sciences, who told Reuters, …
Anthropic has established physical biology wet labs and hired bench scientists to let its Claude models conduct real-world drug discovery experiments, targeting rare and neglected diseases. The initia…
Anthropic launched its invite-only Life Sciences Verification Program on September 17, a gated beta granting qualifying organizations access to its biology-focused models including Mythos 5.1, Opus 5,…
Novo Nordisk, the Danish developer of Ozempic, announced Wednesday a partnership with Anthropic to use Anthropic's Claude model to advance drug discovery research and development and aid its own softw…
Novo Nordisk is partnering with Anthropic to apply Claude Science and other AI models to drug discovery, the companies said in a Sept. 16 statement. Novo Nordisk will test Claude Science on selected R…
Novo Nordisk has partnered with Anthropic to integrate Claude models into its drug discovery and development pipeline, the companies said Wednesday, September 16, 2026. The Danish pharmaceutical compa…
Novo, the Danish pharmaceutical company formerly known as Novo Nordisk, announced a partnership with Anthropic to use the AI company's models and Claude Science in its drug research, with Novo CEO Mik…
Microsoft is positioning its "AI for Better Health" initiative and its new Microsoft Discovery platform as the centerpiece of pharmaceutical AI adoption, with Novo Nordisk building a governed AI reaso…
Anthropic announced on August 27 that it is releasing 10,000 Claude subscription seats for scientists, offering free standard access or premium seats at $15 per month for a year, and expanding its AI …
Big Pharma's second-quarter earnings calls highlighted the growing role of AI in drug development and the intensifying oral GLP-1 competition between Novo Nordisk and Eli Lilly, alongside leadership c…
Nestle is using artificial intelligence and nutritional science to develop products for the millions of Americans taking GLP-1 weight-loss drugs such as Ozempic and Wegovy, aiming to turn the rise of …
Enterprises rushing to deploy generative and agentic AI are repeating mistakes from the RPA era, according to technology leaders at Globant, Novo Nordisk, and Purpose Legal. Agustin Huerta, SVP of dig…
Abbott launched Libre Assist, an AI-powered tool using image recognition to predict how meals affect glucose levels, at CES on January 5, 2026. The feature extends the FreeStyle Libre continuous gluco…
SpaceX (SPCX) will report its first earnings as a public company on Tuesday, with shares down nearly 30% from their $150 IPO debut last month. The July jobs report, due Friday, is expected to show 88,…
Denmark's Centre for Biosecurity and Biopreparedness (CBB) assesses that current AI chatbots pose limited bioweapon risk to novices due to hallucinations, but offer significant advantages to competent…
A secret shopper survey by Yale University researchers published in JAMA found that nearly half of 49 online GLP-1 telehealth providers failed to ask about diet, physical activity, or eating disorders…